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ABSTRACT 19 
Clostridium difficile is the dominant cause of pseudomembranous colitis in nosocomial 20 
environments. C. difficile infection (CDI) generally affects elderly (≥ 65) hospital in-patients 21 
who have received broad spectrum antimicrobial treatment. CDI has a 30% risk of reinfection 22 
and subsequent 60% risk of relapse thereafter, leading to a high economic burden of over 7 23 
billion pounds sterling and over 900,000 cases in the USA and Europe per annum. With the 24 
long-term consequences of faecal transplantation currently unknown, and limited spectrum of 25 
effective antibiotics, there is an urgent requirement for alternative means of preventing and 26 
treating CDI in high risk individuals. Metagenomics has recently improved our understanding 27 
of the colonisation resistance barrier and how this could be optimised. pH, oxidation-28 
reduction potentials and short chain fatty acids have been suggested to inhibit C. difficile 29 
growth and toxin production in vitro and in vivo studies. This review aims to pull together the 30 
evidence in support of a colonisation resistance barrier against CDI. 31 
 32 
  33 
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INTRODUCTION 34 
Clostridium difficile is an obligate anaerobic, heterotrophic, rod-shaped, ‘drumstick’ bacillus. 35 
(1 - 2) C. difficile is a toxigenic and proteolytic organism that was originally entitled 36 
‘difficile’ due to its difficulty to isolate and cultivate (1). Several refined mechanisms 37 
contribute to the ability of C. difficile to survive within the environment, transmit and 38 
colonise within the host. C. difficile colonisation has been attributed to its ability to germinate 39 
from a dormant, highly-resistant spore form and to produce toxins (TcdA, TcdB and binary 40 
toxin) which has been suggested to hamper the adaptive immune response and influence the 41 
surrounding colonic environment (3).  42 
 43 
C. DIFFICILE PATHOGENICITY 44 
C. difficile spores have the ability to survive on a wide variety of surfaces and are ethanol 45 
resistant (4). These spores are transmitted to the host via the faecal/oral route where they 46 
begin to germinate within the small intestinal area into a vegetative cell form (1). Virulence 47 
factors such as adherence, achieved by S-layer high molecular weight protein, chemotaxis 48 
and motility via flagella (5 - 6) may further aid C. difficile colonisation of the colon. CDI is 49 
generally observed in elderly individuals with low microbial diversity, and those enduring 50 
antimicrobial treatments (1). The colonisation resistance barrier in the normal healthy colon 51 
is the result of high microbial diversity, substrate/area competition, immune response 52 
modulation and short chain fatty acid production (6 - 7).  53 
Following colonisation of the large intestine, C. difficile initiates exponential growth, during 54 
which hydrolytic enzymes such as collagenase, chodrointin-4-sulphatase and hyaluronidase 55 
are produced, which results in epithelial cell inflammation, cell cytotoxicity and may 56 
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stimulate the release of further nutrients (8). At the stationary phase of growth, the production 57 
of toxins from C. difficile, toxin A (TcdA) and B (TcdB), peak (3). Both are encoded on the 58 
pathogenicity locus; TcdA is an enterotoxin which enters the cell through endocytosis and is 59 
activated through subsequent acidification, and TcdB is a cytotoxin activated by autocatalytic 60 
cleavage within the endolysosomal compartment. Both TcdA and TcdB inactivate the Rho-61 
GTPases which regulate actin production within the epithelial cytoskeleton, which leads to 62 
cell rounding, cell shrinking and apoptosis within 24 hours, ultimately resulting in increased 63 
permeability and loss of barrier function (3, 5, 9 - 10).  Certain strains of C. difficile, 64 
particularly hyper-virulent ribotypes, produce binary toxin which catalyses glucosylation to 65 
induce disorganisation of the actin in the cytoskeleton (10). Hyper-virulent strains of C. 66 
difficile, such as B1-NAP1-027 and 078 have been identified as toxin overproducers, which 67 
may account for their emergence as major pathogens with a mortality rate of 37% (1). 68 
With approximate figures of around 900,000 cases per year, resulting in an annual economic 69 
burden of £7 billion in Europe and the USA (11), there is an urgent requirement for effective 70 
novel treatments for C. difficile infection (CDI). Recent advances have involved 71 
characterising and transplanting a “healthy” microbial flora into infected patients in a bid to 72 
restore colonisation resistance from apparently healthy subjects. Current preventative 73 
measures and treatment recommendations for CDI involve stricter broad spectrum antibiotic 74 
stewardship, discontinuation of antibiotic treatment and an arduous regimen of 75 
metronidazole, or vancomycin in more severe cases (12). Both antimicrobials are associated 76 
with as high as a 35% risk of recurrence or reinfection after initial infection (13). These 77 
relatively high recurrence rates suggest a requirement to switch the focus to other treatments 78 
that preserve susceptible intestinal bacteria required for a healthy colonic environment (12). 79 
This review looks at the current status of C. difficile research and the requirement for new, 80 
novel treatments and preventative methods. Potential intervention methods that restore the 81 
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inter-regulatory mechanisms involved in shaping the colonisation resistance barrier and 82 
optimal environment for growth of indigenous bacteria are reviewed to highlight 83 
physiologically relevant methods which could be implemented in human interventions.  84 
  85 
C. DIFFICILE EPIDEMIOLOGY 86 
The epidemiological profile and severity of CDI has changed significantly over the 87 
last decade. An increased incidence of outbreaks caused by closely-related strains was 88 
reported in the USA, Canada and Europe with the increased emergence of hypervirulent 89 
strains (6, 13 - 18). The rates of CDI vary between countries worldwide. CDI infection rates 90 
are lower in some areas of Europe (14 - 15), such as the Netherlands (14), due to the 91 
improvement of prevention, antibiotic stewardship, monitoring and reporting methods when 92 
dealing with the infection (16). Areas such as Chile have noted an increase and rapid spread 93 
of C. difficile ribotype NAP1/BI/027, which has accounted for 79% of cases (19). In North 94 
America in 2000, however, an increase in the incidence of CDI was noted from 0.68% to 95 
1.2% of hospitalised patients, with 3.2% of these developing life-threatening symptoms (17). 96 
Patients in North America who have received antimicrobial treatment and have recently 97 
visited hospital, either as an outpatient or otherwise, have high CDI risk; only 20% of all CDI 98 
cases are community-associated (17). Queensland has noted an emergence of binary toxin 99 
ribotype UK 244, a genetic relative of 027 (20) whilst, within the UK, a decline in the 100 
incidence of ribotype 027 has been noted while ribotype 078 has emerged as a prominent 101 
cause for concern (21). Significant outbreaks in the UK from 2003-2005 involved the 102 
hypervirulent ribotype 027 resulted in an 11-12% mortality rate from both outbreaks (22). 103 
Davies et al., (2014) also reported that there are approximately 40,000 cases of CDI that are 104 
undiagnosed amongst European inpatients (23). Consequently, under-diagnosis impacts upon 105 
monitoring the epidemiology of CDI and successful treatment of the infection (23).   106 
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DIAGNOSIS OF C. DIFFICILE INFECTION 107 
Diagnostic guidelines dictate that only samples of diarrhoea or unformed stools are to be used 108 
for testing, with the exception of ileal fluid that is suspected of CDI (12). Positive diagnosis 109 
of CDI is defined as the presence of symptoms, generally diarrhoea and a positive stool 110 
sample, with identification of C. difficile toxins or toxigenic bacteria with the use of cytotoxin 111 
assays, enzyme immunoassay or polymaerase chain reaction (PCR) (12, 24). In other cases, 112 
diagnosis can be made by histopathological or colonoscopic findings revealing 113 
pseudomembranous colitis (12). The method with the highest sensitivity for the diagnosis of 114 
C. difficile infection is stool culture (12 - 24). However this is not practical for use as the 115 
standard diagnostic method as it has a long turnaround time and is not sufficiently specific 116 
due to the possibility of isolating non-toxigenic strains. Stool culture is recommended during 117 
epidemiological studies (12) and should be coupled with toxigenic culture to identify a 118 
standard for comparison to other clinical testing methods (12, 24).  119 
 120 
Enzyme immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA) are 121 
considered insufficient as the sole means of CDI diagnosis due to low sensitivity compared 122 
with other methods (12). These assay methods are, however, rapid and inexpensive 123 
techniques (6) and thus have been suggested for use if coupled with other more sensitive 124 
methods (12). Cytotoxin assays are presently considered to be the gold standard diagnostic 125 
methods used (12, 20, 24). This technique should be used in combination with an EIA, which 126 
screens for glutamate dehydrogenase, due to cytotoxin assays being time-consuming and 127 
having relatively low sensitivity in comparison with stool culture (12). 128 
 129 
Genotyping methods have been of particular importance in the rapid detection, with good 130 
sensitivity and specificity (6, 12), these methods are increasingly utilised throughout Europe 131 
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although more data is required before they can be recommended as a routine method for 132 
diagnosis (6, 12). Several genotyping methods, such as pulse field gel electrophoresis, widely 133 
used in the US (6), and multi-locus variable number tandem repeat analysis (MLVA) has 134 
been used in epidemiological studies but is not considered an efficient method of diagnosis 135 
(25). MLVA is a widely used method for epidemiology, transmission and genotype studies 136 
and has been used to assess toxigenic C. difficile isolates within a hospital environment and to 137 
assess the role of asymptomatic C. difficile carriers in infection transmission (25).  138 
  139 
TREATMENTS FOR C. DIFFICILE INFECTION  140 
The recommended first-line treatment after CDI diagnosis is discontinuation of current 141 
antibiotic therapy followed by administration of metronidazole or vancomycin, dependent on 142 
infection severity or instance of recurrence (12). CDI bares a 35% risk of re-infection or 143 
relapse when treated with metronidazole or vancomycin (13), bringing the effectiveness of 144 
these antibiotics into question.  145 
Other treatments such as Fidaxomicin, a macrocylic antibiotic which targets the protein 146 
sheath (26) and SMT 19969, a heterocyclic non-absorbable agent, which has a high 147 
selectivity for C. difficile over other members of the microbiota (27), have recently been 148 
reviewed and suggested as potential ‘new antibiotics’ for CDI. Studies have shown that both 149 
Fidaxomicin (currently in Phase III development) and SMT 19969 (in Phase II development) 150 
are more selective for C. difficile than metronidazole and vancomycin and thus would be less 151 
damaging to the intestinal flora (26 - 28), but these require further trials and elucidation of 152 
cost before they can replace the current antibiotics of choice. As the current treatments for 153 
CDI involve further administration of antibiotics, attempts have been made to identify other 154 
means of therapy. 155 
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Probiotic interventions have been suggested in previous studies, specifically involving the use 156 
of Lactobacilli and Bifidobacteria, common bacterial groups that comprise part of the normal 157 
microbiota (29). Although some success has been reported, evidence remains inconsistent 158 
and no overall therapeutic efficacy can be drawn from basic probiotic treatments consisting 159 
of single bacterial strains (30). Restoration of the faecal microbiome has been investigated in 160 
the form of faecal transplantation. In the case of recurrent CDI and antibiotic refractory 161 
diseases, faecal transplantation of healthy donor faeces has boasted high success rates (31). 162 
Single methods of preparation of donor faeces and faecal microbial transplantation 163 
administration have demonstrated inconsistent success and it has been suggested that in 164 
future faecal transplantations are tailored to the individual patients (30). The full 165 
consequences of faecal transplantation of a donor’s indigenous flora are not fully understood 166 
but may involve risk of infection from opportunistic pathogens harmless to the donor, or the 167 
effect of the flora on the recipient’s mental wellbeing and potential consequences to weight 168 
loss or gain (12, 32). 169 
 170 
An effective treatment for CDI would prevent or inhibit the growth and/or toxin production 171 
of C. difficile whilst promoting the re-colonisation of the host’s own microbiome. An ideal 172 
treatment would not involve arduous administration of antibiotics, would eliminate the 173 
challenge for patient of accepting donor faeces and would minimise the risk of potential long 174 
term consequences. 175 
 176 
 177 
 178 
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THE HEALTHY MICROBIOTA AND THE COLONIC ENVIRONMENT AND THE 179 
EFFECT OF BROAD SPECTRUM ANTIBIOTICS  180 
An individual’s gut microbiome is possibly unique and its diversity depends on the method of 181 
birth, whether breast fed or bottle fed in infancy and the individual’s diet and lifestyle 182 
thereafter (33). The adult bacterial population of the colon contains approximately 1011-1012 183 
bacteria per gram of faecal content (34). Recent advances in metagenomic techniques have 184 
improved our understanding of the indigenous flora and the environmental niches which 185 
specific bacterial groups occupy (35). Although many members of the diverse microbiome 186 
are not yet cultivable, it is understood that there are groups of phylogenetically diverse 187 
bacteria which coexist harmoniously within the gut of each individual. The gut microbiome is 188 
dominated at the phylum level by Bacteroidetes and Firmicutes, with abundant taxa 189 
represented by some of the more dominant genera such as Bacteroides and Prevotella 190 
alongside a host of less abundant taxa such as Bifidobacteria and Lactobacilli (36). This 191 
microbial ecosystem is known to inter-regulate the intestinal environment alongside 192 
environmental mediators such as pH and oxidation-reduction potentials (ORP) and nutrient 193 
availability (7). The microbes present within the colon are known to contribute to 194 
environmental ORP through H2S production, and conversely ORP influences bacterial 195 
colonisation by controlling areas which bacteria grow in to within a particular niche (37). 196 
Microaerophillic bacteria, for instance, will grow alongside epithelial cells whereas more 197 
anaerobic bacteria will occupy niches further into the lumen, at a more negative ORP (37). 198 
ORP is also influenced by a series of redox couples; the glutathione and thiol redox couple 199 
(GSSG/GSH), the cysteine redox couple (CyS/CySS) and thioredoxin (Trx) (38). 200 
Inflammation is likely to increase ORP due to the mucosal immune response and efflux of O2 201 
into the epithelial environment (37) (Figure 1).  202 
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The microbiota also produce the short chain fatty acids (SCFA) acetate, propionate, and 203 
butyrate as the main fermentation products (7). They perform a variety of important roles 204 
within the gut including resistance to pathogens (7). SCFA along with lactate are the major 205 
drivers towards acidic pH in the colon.. The pH within the intestine controls bacterial survival 206 
via disruption of the cell or provision of a niche. The pH of the colon can range between 5 – 7 207 
dependent on whether the individual is fasted or fed and also on the amount of dietary fibre 208 
consumed in their diet and some gut microbes are sensitive to pH within the physiological 209 
range of the intestine (39). 210 
Broad spectrum antibiotics such as cephalosporins, ciprofloxacin, clindamycin, amoxicillin 211 
and clavulanic acid have been found to decrease Bifidobacterium spp., Enterobacteriacea, 212 
Lactobacilli and Bacteroidetes as well as other gram positive anaerobes (40). Any disruption 213 
to the fragile balance between bacteria and environment via introduction of antibiotics 214 
decreases the diversity of bacteria and therefore is likely to adversely affect the colonisation 215 
resistance barrier as shown in Figure 1.  In a study on the effect of neomycin on the luminal 216 
pH of rabbits, a significant increase was observed in pH from 6.07 to 6.66 (41). In elderly 217 
patients, with already diminished microbial diversity due to decreased bowel motility, 218 
nutrient production and constipation (42), and prescribed broad spectrum antimicrobial 219 
treatments, the collapse of the colonisation resistance barrier makes way for opportunistic 220 
pathogens such as C. difficile (1). Understanding the mechanisms that regulate C. difficile 221 
colonisation in the high risk cohort would allow for the development of targeted therapies.222 
  223 
 224 
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 225 
Figure 1: The proposed effect of antimicrobials on the colonisation resistance barrier. As the microbial 226 
diversity drops short chain fatty acid concentrations may also decrease in the colon which would cause a 227 
rise in pH (43). Dysbiosis also leads to a mucosal immune response and subsequent inflammation which 228 
increases ORP (37). 229 
 230 
PROSPECTIVE AVENUES FOR OPTIMISATION OF THE COLONISATION 231 
RESISTANCE BARRIER AND MODES OF INTERVENTION 232 
Recent metagenomic techniques have allowed greater insight into the gut microbiome and 233 
have advanced our understanding of the role of the microbiome in human health (35). 234 
Probiotics such as Bifidobacterium longum, Lactobacillus acidophilus and Bacteroides 235 
fragilis may serve to inter-regulate the environment of the colon and loss of diversity. 236 
Bifidobacteria and Lactobacilli have been linked to suppression of opportunistic pathogens 237 
such as C. difficile (1, 29). Restoration of lost bacterial quantity and diversity through FMT 238 
has also shown great promise as a technique for restoring the colonisation resistance barrier 239 
and preventing C. difficile recurrence (31). 240 
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 In vitro, pH and SCFA regulate C. difficile where decreased pH and physiological 241 
concentrations of butyrate are inhibitory to C. difficile growth (7, 43). However, few clinical 242 
studies exist where a systematic approach to restoring the colonisation resistance barrier has 243 
been undertaken. Vegetative cells are sensitive to SCFA, most notably butyrate, at 244 
physiological concentrations of approximately 160 mM (43). Acetate also produced a 245 
protective epithelial cell response in a murine model from Escherichia coli 0157:H7 (44) 246 
Vegetative cells are sensitive to acidic pH and fully germinate by the time they reach the 247 
colon. Evidence suggests that the physiological pH within the colon can drop as low as 5 248 
(39), which is shown to be well within the inhibitory range for C. difficile vegetative cells (7, 249 
43), thus indicating a potential route for intervention by manipulating the pH of the intestine. 250 
Fermentable fibres, such as inulin, act as substrates for the colonic microbiota and can 251 
selectively promote the growth of probiotic bacteria (43). Fermentation of dietary fibre 252 
results in a decrease in luminal pH through increased SCFA production, both of which inhibit 253 
C. difficile growth (7, 43 - 44).   Increased SCFA production is also associated with an 254 
improved innate immune response, reducing inflammation and alleviation of symptoms in 255 
IBD patients (7, 45 - 46). There is also the potential to introduce physiological concentrations 256 
of SCFA directly into the large intestine, through direct instillation (although realistically 257 
limited to the distal colon in patients), through encapsulation strategies or targeted delivery.  258 
  259 
Oxidation-reduction potentials have also been found in to impact on toxin production of C. 260 
difficile (47). Altering the ORP from -360 mV to +100 mV was found to increase toxin 261 
production 100-fold, which has significant relevance to understanding the mechanisms which 262 
promote increased toxin production within the colon of a CDI patient (47). Therefore, if ORP 263 
can be modulated by GSH supplementation, this presents a further method for optimising the 264 
colonisation resistance barrier against C. difficile colonisation (38, 48). C. difficile growth and 265 
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toxin production has been shown to be affected by pH, SCFA and ORP within physiological 266 
ranges. Manipulation of the colonic environment has been suggested as a clinical avenue for 267 
prevention and treatment, but it has never been systematically investigated (7). If an optimum 268 
inhibitory range for ORP, pH and SCFA can be established in vitro, then a strategy for 269 
translating this to the human intestine (the colonisation resistance barrier) could be explored. 270 
.  271 
CONCLUSION 272 
C. difficile infection is a worldwide problem, and although there have been advances in 273 
treatments, it still remains a significant economic burden which cannot be ignored. There is 274 
rationale for further understanding and taking advantage of the effect of the colonisation 275 
resistance barrier within the colon. Re-establishing normal physiological parameters in the 276 
colon, harmless to indigenous flora and colonisation but inhibitory to either C. difficile 277 
growth or production of virulence factors would prove a useful tool in the battle against CDI 278 
as a worldwide burden. Dietary and targeted delivery approaches that manipulate the 279 
colonisation resistance barrier are worthy of further investigation because they represent a 280 
low risk option for treatment but more importantly may offer solution in prevention of CDI. 281 
 282 
 283 
 284 
 285 
 286 
 287 
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